Literature DB >> 20738009

Chemotherapy associated central nervous system damage.

Jörg Dietrich1.   

Abstract

Chemotherapy is commonly associated with harmful effects to multiple organ systems, including the central nervous system (CNS). Neurotoxicity may manifest as both acute and delayed complications, which is particularly a concern for long-term survivors. Patients may experience a wide range of neurotoxic syndromes, ranging from neuro-vascular complications and focal neurological deficits to generalized neurological decline with cognitive impairment, cortical atrophy and white matter abnormalities. Along with the use of more aggressive and combined treatment modalities and prolonged survival of cancer patients, neurological complications have been observed with increasing frequency. The mechanisms by which cancer therapy, including chemotherapy and radiation, result in neurological complications, have been poorly understood. Recent studies have now started to unravel the cell-biological basis for commonly seen neurotoxic syndromes and have provided compelling explanations for delayed neurological complications, such as cognitive decline, progressive myelin disruption and brain atrophy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20738009     DOI: 10.1007/978-1-4419-6306-2_11

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  17 in total

1.  Brain network alterations and vulnerability to simulated neurodegeneration in breast cancer.

Authors:  Shelli R Kesler; Christa L Watson; Douglas W Blayney
Journal:  Neurobiol Aging       Date:  2015-05-01       Impact factor: 4.673

2.  Effects of thioTEPA chemotherapy on cognition and motor coordination.

Authors:  Tyler C Alexander; Frederico Kiffer; Thomas Groves; Julie Anderson; Jing Wang; Abdallah Hayar; Michelle T Chen; Analiz Rodriguez; Antiño R Allen
Journal:  Synapse       Date:  2019-03-14       Impact factor: 2.562

3.  Altered resting state functional brain network topology in chemotherapy-treated breast cancer survivors.

Authors:  Jennifer Bruno; S M Hadi Hosseini; Shelli Kesler
Journal:  Neurobiol Dis       Date:  2012-07-20       Impact factor: 5.996

4.  Default mode network connectivity distinguishes chemotherapy-treated breast cancer survivors from controls.

Authors:  Shelli R Kesler; Jeffrey S Wefel; S M Hadi Hosseini; Maria Cheung; Christa L Watson; Fumiko Hoeft
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-24       Impact factor: 11.205

5.  Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors.

Authors:  Shelli Kesler; Michelle Janelsins; Della Koovakkattu; Oxana Palesh; Karen Mustian; Gary Morrow; Firdaus S Dhabhar
Journal:  Brain Behav Immun       Date:  2012-06-12       Impact factor: 7.217

6.  MEK1/2 inhibition suppresses tamoxifen toxicity on CNS glial progenitor cells.

Authors:  Hsing-Yu Chen; Yin Miranda Yang; Ruolan Han; Mark Noble
Journal:  J Neurosci       Date:  2013-09-18       Impact factor: 6.167

7.  Cognitive impact of cytotoxic agents in mice.

Authors:  R Seigers; M Loos; O Van Tellingen; W Boogerd; A B Smit; S B Schagen
Journal:  Psychopharmacology (Berl)       Date:  2014-06-04       Impact factor: 4.530

8.  Neurotoxic Effects of Anthracycline- vs Nonanthracycline-Based Chemotherapy on Cognition in Breast Cancer Survivors.

Authors:  Shelli R Kesler; Douglas W Blayney
Journal:  JAMA Oncol       Date:  2016-02       Impact factor: 31.777

9.  Bone marrow mesenchymal stem cells and their derived exosomes resolve doxorubicin-induced chemobrain: critical role of their miRNA cargo.

Authors:  Marwa O El-Derany; Mohamed H Noureldein
Journal:  Stem Cell Res Ther       Date:  2021-06-05       Impact factor: 6.832

Review 10.  Role of Polymeric Local Drug Delivery in Multimodal Treatment of Malignant Glioma: A Review.

Authors:  Yuan-Yun Tseng; Tai-Yuan Chen; Shih-Jung Liu
Journal:  Int J Nanomedicine       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.